Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.

INTRODUCTION AND AIMS To examine Australian opioid substitution treatment (OST) prescribers' perceptions of (i) diversion and/or injection of methadone, buprenorphine, buprenorphine-naloxone by patients; and (ii) effectiveness of current treatment policies in minimising the associated risks. DESIGN AND METHODS 1278 authorised OST prescribers, identified by each jurisdiction's health department records, were sent a postal survey in 2007. Reminder letters and additional copies of the survey were sent to non-responders at weeks four and eight following the initial mail-out. Respondents went into a draw to win one of ten $100 book vouchers. RESULTS Although the response rate was 26% (N = 291), participating prescribers served half (49%) of all OST patients in Australia. Prescribers perceived more buprenorphine patients removed supervised doses (7%) and diverted unsupervised doses (20%), compared with methadone patients (1% and 4% respectively) and buprenorphine-naloxone patients (3% and 2% respectively). Prescribers reported significantly more buprenorphine and buprenorphine-naloxone patients injected doses (5% respectively), compared with methadone patients (2%). Non-adherence was identified through patient self-report (51%), and the reports of pharmacists (49%) and other staff (34%). More prescribers were confident in assessing the risk of injection (54%) than diversion (37%). Many prescribers responded 'don't know' to quantitative survey items. Qualitative responses highlighted uncertainties in assessing diversion/injection and whether current responses constituted 'best practice'. DISCUSSION AND CONCLUSIONS Australian prescribers perceive most patients adhere with OST, although they may underestimate the levels of diversion. Prescribers' beliefs about patients' behaviours are important and influence decisions to prescribe, medication choice and suitability for unsupervised dosing. The uncertainties in assessing and responding to diversion/injection may be a factor deterring prescribers' participation in OST.

[1]  A. Winstock,et al.  Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. , 2010, Addiction.

[2]  M. Clarke,et al.  Methods to increase response to postal and electronic questionnaires. , 2009, The Cochrane database of systematic reviews.

[3]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[4]  A. Winstock,et al.  What Is Diversion of Supervised Buprenorphine and How Common Is It? , 2009, Journal of addictive diseases.

[5]  S. Meghani,et al.  Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. , 2009, Pain medicine.

[6]  R. Chou,et al.  Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. , 2009, The journal of pain : official journal of the American Pain Society.

[7]  A. Winstock,et al.  Methods and Motivations for Buprenorphine Diversion from Public Opioid Substitution Treatment Clinics , 2009, Journal of addictive diseases.

[8]  W. Dubin,et al.  Medication Adherence: A Review of the Literature and Implications for Clinical Practice , 2009, Journal of psychiatric practice.

[9]  A. Winstock,et al.  Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. , 2008, The International journal on drug policy.

[10]  S. Passik,et al.  Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. , 2008, Pain medicine.

[11]  C. Aitken,et al.  A very low response rate in an on‐line survey of medical practitioners , 2008, Australian and New Zealand journal of public health.

[12]  N. Lee,et al.  Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. , 2007, Drug and alcohol review.

[13]  J. Inciardi,et al.  Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. , 2007, Pain medicine.

[14]  S. Fraser,et al.  Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice , 2007 .

[15]  Christian R. Dolder,et al.  A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. , 2006, The Journal of clinical psychiatry.

[16]  S. Fraser.  The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects , 2006 .

[17]  S. Passik,et al.  Pain and Aberrant Drug-Related Behaviors in Medically Ill Patients With and Without Histories of Substance Abuse , 2006, The Clinical journal of pain.

[18]  A. Pelet,et al.  Difficulties associated with outpatient management of drug abusers by general practitioners. A cross-sectional survey of general practitioners with and without methadone patients in Switzerland , 2005, BMC family practice.

[19]  L. Webster,et al.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. , 2005, Pain medicine.

[20]  Gordon Flowerdew,et al.  Health care restructuring and family physician care for those who died of cancer , 2005, BMC family practice.

[21]  S. Passik,et al.  The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. , 2003, Pain medicine.

[22]  R. Mattick,et al.  Methadone-related and heroin-related deaths among opiate users: methadone helps save lives. , 2003, Addiction.

[23]  I. Varescon,et al.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. , 2003, Drug and alcohol dependence.

[24]  R. Richmond,et al.  The general practitioner's role in AOD issues: overcoming individual, professional and systemic barriers. , 2002, Drug and alcohol review.

[25]  D. Torgerson,et al.  Increasing response rates to postal questionnaires , 2002, BMJ : British Medical Journal.

[26]  D. Cranston,et al.  Patients in methadone maintenance treatment who inject methadone syrup: a preliminary study. , 2000, Drug and alcohol review.

[27]  J. Fountain,et al.  Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. , 2000, Addiction.

[28]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[29]  J. Saunders,et al.  General practitioners' experiences of patients with drug and alcohol problems. , 1991, British journal of addiction.

[30]  A. Winstock,et al.  THE DIVERSION AND INJECTION OF THE PHARMACEUTICAL OPIOIDS USED IN OPIOID SUBSTITUTION TREATMENT: Findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone, 2006-2008 , 2009 .

[31]  K. Chien,et al.  BMC Cardiovascular Disorders BioMed Central , 2006 .